Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Purple Biotech Ltd ADR (NQ: PPBT )

0.3700 UNCHANGED
Streaming Delayed Price Updated: 3:50 PM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 401
Open 0.3700
Bid (Size) 0.3696 (1)
Ask (Size) 0.3799 (1)
Prev. Close 0.3700
Today's Range 0.3700 - 0.3700
52wk Range 0.3120 - 1.800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds
From Purple Biotech Ltd.
Via GlobeNewswire

Performance

YTD
-51.99%
-51.99%
1 Month
-21.28%
-21.28%
3 Month
-28.29%
-28.29%
6 Month
-39.34%
-39.34%
1 Year
-68.64%
-68.64%

More News

Read More
Why Purple Biotech (PPBT) Shares Are Trading Lower
Via Benzinga
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
PPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
From Purple Biotech Ltd.
Via GlobeNewswire
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
Via InvestorPlace
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
From Purple Biotech Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
From Purple Biotech Ltd.
Via GlobeNewswire
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
From Purple Biotech Ltd.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.